Adjuvant Chemotherapy for Early-Stage Breast Cancer

American Cancer Society. Available at: http://www.cancer.org. Berry, 2005, Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med, 353, 1784, 10.1056/NEJMoa050518 Elkin, 2006, Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort, J Clin Oncol, 24, 2757, 10.1200/JCO.2005.03.6053 Saphner, 1996, Annual hazard rates of recurrence for breast cancer after primary therapy, J Clin Oncol, 14, 2738, 10.1200/JCO.1996.14.10.2738 Chia, 2004, Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies, J Clin Oncol, 22, 1630, 10.1200/JCO.2004.09.070 Susnik, 2004, Occult micrometastases in axillary lymph nodes predict subsequent distant metastases in stage I breast cancer: a case-control study with 15-year follow-up, Ann Surg Oncol, 11, 568, 10.1245/ASO.2004.10.021 Cummings, 2002, Occult axillary lymph node metastases in breast cancer do matter: results of 10-year survival analysis, Am J Surg Pathol, 26, 1286, 10.1097/00000478-200210000-00005 Millis, 2002, Occult axillary lymph node metastases are of no prognostic significance in breast cancer, Br J Cancer, 86, 396, 10.1038/sj.bjc.6600070 Elson, 1993, Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma. A study of 97 cases, Anal Quant Cytol Histol, 15, 171 Herbert, 2007, The impact of nodal isolated tumor cells on survival of breast cancer patients, Am J Surg, 193, 571, 10.1016/j.amjsurg.2007.01.007 Berry, 2006, Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer, JAMA, 295, 1658, 10.1001/jama.295.14.1658 Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 1659, 10.1056/NEJMoa052306 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Pritchard, 2006, HER2 and responsiveness of breast cancer to adjuvant chemotherapy, N Engl J Med, 354, 2103, 10.1056/NEJMoa054504 Paik, 1998, erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer, J Natl Cancer Inst, 90, 1361, 10.1093/jnci/90.18.1361 Thor, 1998, erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer, J Natl Cancer Inst, 90, 1346, 10.1093/jnci/90.18.1346 Tanner, 2006, Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401, J Clin Oncol, 24, 2428, 10.1200/JCO.2005.02.9264 O'Malley FP, Chia S, Tu D, et al. Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Atlanta, 2006. Marty, 2005, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol, 23, 4265, 10.1200/JCO.2005.04.173 Joensuu, 2006, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer, N Engl J Med, 354, 809, 10.1056/NEJMoa053028 Schiff, 2003, Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs), Breast Cancer Res, 5, 228, 10.1186/bcr626 Ellis, 2001, Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial, J Clin Oncol, 19, 3808, 10.1200/JCO.2001.19.18.3808 Kaufman B. Trastuzumab + anastrozole in postmenopausal women with HER2 positive, HR-positive MBC: results of the TAnDEM study. Presented at the European Society for Medical Oncology (ESMO) Meeting. Istanbul, Turkey, 2006. Olivotto, 2005, Population-based validation of the prognostic model ADJUVANT! for early breast cancer, J Clin Oncol, 23, 2716, 10.1200/JCO.2005.06.178 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and a 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 351, 2817, 10.1056/NEJMoa041588 van de Vijver, 2002, A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med, 347, 1999, 10.1056/NEJMoa021967 Lohrisch, 2006, Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer, J Clin Oncol, 24, 4888, 10.1200/JCO.2005.01.6089 Wolmark, 2001, Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18, J Natl Cancer Inst Monogr, 96, 10.1093/oxfordjournals.jncimonographs.a003469 Fisher, 2004, Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials, J Natl Cancer Inst, 96, 1823, 10.1093/jnci/djh338 Heys, 2002, Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial, Clin Breast Cancer, 3, S69, 10.3816/CBC.2002.s.015 Bear HD, Anderson S, Smith RE, et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Presented at the San Antonio Breast Cancer Symposium. San Antonio, 2004. Bonadonna, 1976, Combination chemotherapy as an adjuvant treatment in operable breast cancer, N Engl J Med, 294, 405, 10.1056/NEJM197602192940801 Bonadonna, 1995, Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) in node positive breast cancer: the results of 20 years of follow-up, New Engl J Med, 332, 901, 10.1056/NEJM199504063321401 Fisher, 1989, A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors, N Engl J Med, 320, 479, 10.1056/NEJM198902233200802 Fisher, 2004, Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials, Lancet, 364, 858, 10.1016/S0140-6736(04)16981-X Fisher, 1997, Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer, J Natl Cancer Inst, 89, 1673, 10.1093/jnci/89.22.1673 2002, International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial, J Natl Cancer Inst, 94, 1054, 10.1093/jnci/94.14.1054 Fisher, 1990, J Clin Oncol, 8, 483, 10.1200/JCO.1990.8.9.1483 Levine, 1998, Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer, J Clin Oncol, 16, 2651, 10.1200/JCO.1998.16.8.2651 Mouridsen, 1999, Adjuvant anthracycline in breast cancer: improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin, J Clin Oncol, 18 Henderson, 2003, Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer, J Clin Oncol, 21, 976, 10.1200/JCO.2003.02.063 Mamounas, 2005, Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28, J Clin Oncol, 23, 3686, 10.1200/JCO.2005.10.517 Martin, 2005, Adjuvant docetaxel for node-positive breast cancer, N Engl J Med, 352, 2302, 10.1056/NEJMoa043681 Roché H, Fumoleau P, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Presented at the San Antonio Breast Cancer Symposium. San Antonio, 2004. Jones, 2005, Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer, J Clin Oncol, 23, 5542, 10.1200/JCO.2005.02.027 Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. New Orleans, 2004. Sparano, 2005, Breast Cancer Res Treat, 94 Fisher, 1997, Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from national surgical adjuvant breast and bowel project B-22, J Clin Oncol, 15, 1858, 10.1200/JCO.1997.15.5.1858 Fisher, 1999, Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25, J Clin Oncol, 17, 3374, 10.1200/JCO.1999.17.11.3374 Budman, 1998, Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer, J Natl Cancer Inst, 90, 1205, 10.1093/jnci/90.16.1205 Piccart, 2001, Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer, J Clin Oncol, 19, 3103, 10.1200/JCO.2001.19.12.3103 Levine, 2005, J Clin Oncol, 23, 5166, 10.1200/JCO.2005.09.423 2001, French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of french adjuvant study group 05 randomized trial, J Clin Oncol, 19, 602, 10.1200/JCO.2001.19.3.602 Bonneterre, 2005, Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial, J Clin Oncol, 23, 2686, 10.1200/JCO.2005.05.059 Galligioni E. Cetto G. Nascimben O. et al. Adjuvant chemotherapy with high dose epirubicin and cyclophosphamide versus cyclophosphamide (EC), methotrexate, fluorouracil (CMF) in high risk premenopausal breast cancer patients: a prospective randomized trial. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Denver, 1997. Peters, 1993, High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer, J Clin Oncol, 11, 1132, 10.1200/JCO.1993.11.6.1132 Rodenhuis, 1998, Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement, Lancet, 352, 515, 10.1016/S0140-6736(98)01350-6 Rodenhuis, 2000, The status of high-dose chemotherapy in breast cancer, Oncologist, 5, 369, 10.1634/theoncologist.5-5-369 Norton, 1988, A Gompertzian model of human breast cancer growth, Cancer Res, 48, 7067 Bonadonna, 1995, Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results, JAMA, 273, 542, 10.1001/jama.273.7.542 Citron, 2003, J Clin Oncol, 21, 1431, 10.1200/JCO.2003.09.081 Hudis C. Dose dense adjuvant chemotherapy for breast cancer. Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Orlando (FL), 2005. Smith, 2006, 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol, 24, 3187, 10.1200/JCO.2006.06.4451 Crump, 2003, Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 21, 3066, 10.1200/JCO.2003.08.137 Shan, 1996, Anthracycline-induced cardiotoxicity, Ann Intern Med, 125, 47, 10.7326/0003-4819-125-1-199607010-00008 Hortobagyi, 2000, Adjuvant therapy for breast cancer, Annu Rev Med, 51, 377, 10.1146/annurev.med.51.1.377 Valagussa, 1994, Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer, Ann Oncol, 5, 209, 10.1093/oxfordjournals.annonc.a058795 Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22(2):322–329. Tan-Chiu, 2005, J Clin Oncol, 23, 7811, 10.1200/JCO.2005.02.4091 Praga, 1979, Adriamycin cardiotoxicity: a survey of 1273 patients, Cancer Treat Rep, 63, 827 Gianni, 2001, Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer, Ann Oncol, 12, 1067, 10.1023/A:1011655503511 Petrek, 2006, Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study, J Clin Oncol, 24, 1045, 10.1200/JCO.2005.03.3969 Shapiro, 2001, Side effects of adjuvant treatment of breast cancer, N Engl J Med, 344, 1997, 10.1056/NEJM200106283442607 Kil, 2006, Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients, Breast Cancer Res Treat, 96, 245, 10.1007/s10549-005-9059-x Parulekar, 2005, Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study–NCIC CTG MA.5, J Clin Oncol, 23, 6002, 10.1200/JCO.2005.07.096 Davis, 2005, Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes, Clin Breast Cancer, 6, 421, 10.3816/CBC.2005.n.046 Fornier, 2005, Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane, Cancer, 104, 1575, 10.1002/cncr.21385